VEGFA

Loading gene…

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 Mutation + VEGFA OverexpressionVEGFA TP531
(functional)	—UNRESOLVED	Functional	B	Supports

Therapy

Cancer

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

TP53 Mutation + VEGFA OverexpressionVEGFA TP531

(functional)

—UNRESOLVED

Functional

Supports

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm	8

Cohort

Mapped cancer

Alteration

Affected (n)

Profiled (n)

Frequency (%)

Rank in cohort

Source

Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022

Colorectal Adenocarcinoma

Ssm

VEGFA Decreased Peri-therapeutic Expression1
Bevacizumab + Fluorouracil + Irinotecan + LevoleucovorinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID818 Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC. PMID 25973082 · Tsai et al., 2015 · Open in CIViC	civic

VEGFA Decreased Peri-therapeutic Expression1

Bevacizumab + Fluorouracil + Irinotecan + LevoleucovorinCombination

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID818

Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.

PMID 25973082 · Tsai et al., 2015 · Open in CIViC

civic

VEGFA low ratio of VEGF165b/VEGFtotal2
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	rejected	EID9296 Tumor samples from the phase III trial of FOLFOX4 bevacizumab were assessed for VEGF165b and VEGFtotal by immunohistochemistry and scored relative to normal mucosal tissue. Low ratio of VEGF165b/VEG… (full text at CIViC) PMID 23104894 · Bates et al., 2012 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	submitted	EID9358 Tumor samples with low ratio of VEGF165b/VEGFtotal treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.49; 95% CI, 0.26 to 0.93). The trend was not significant with p… (full text at CIViC) PMID 23104894 · Bates et al., 2012 · Open in CIViC	civic

VEGFA low ratio of VEGF165b/VEGFtotal2

Bevacizumab

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

rejected

EID9296

Tumor samples from the phase III trial of FOLFOX4 bevacizumab were assessed for VEGF165b and VEGFtotal by immunohistochemistry and scored relative to normal mucosal tissue. Low ratio of VEGF165b/VEG… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

civic

〃

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID9358

Tumor samples with low ratio of VEGF165b/VEGFtotal treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.49; 95% CI, 0.26 to 0.93). The trend was not significant with p… (full text at CIViC)

PMID 23104894 · Bates et al., 2012 · Open in CIViC

civic

VEGFA Overexpression4
Bevacizumab	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7013 We found that high VEGF expression (mean positive area > 5,000 pixels/×400 field) was associated with increased likelihood of achieving radiographic response (P = .024; Table 2). PMID 18182667 · Sathornsumetee et al., 2008 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	3	submitted	EID9229 A meta analysis and systematic review of three trials with a total of 3748 breast cancer patients was undertaken to determine if VEGF-A plasma levels affected patient outcomes in response to bevacizum… (full text at CIViC) PMID 25947646 · Santos et al., 2015 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID7216 Patients with high baseline plasma VEGF-A levels showed a trend toward improved overall survival (hazard ratio [HR], 0.72; 95% CI, 0.57 to 0.93) versus patients with low VEGF-A levels (HR, 1.01; 95% C… (full text at CIViC) PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC	civic
Bevacizumab + ErlotinibCombination	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	2	submitted	EID7237 This phase II trial evaluated the efficacy of bevacizumab+erlotinib in 40 platinum-resistant ovarian cancer patients. No evidence was found associating VEGFR-1 expression and any clinical parameters.… (full text at CIViC) PMID 21041183 · Chambers et al., 2010 · Open in CIViC	civic

VEGFA Overexpression4

Bevacizumab

GlioblastomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID7013

We found that high VEGF expression (mean positive area > 5,000 pixels/×400 field) was associated with increased likelihood of achieving radiographic response (P = .024; Table 2).

PMID 18182667 · Sathornsumetee et al., 2008 · Open in CIViC

civic

〃

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9229

A meta analysis and systematic review of three trials with a total of 3748 breast cancer patients was undertaken to determine if VEGF-A plasma levels affected patient outcomes in response to bevacizum… (full text at CIViC)

PMID 25947646 · Santos et al., 2015 · Open in CIViC

civic

〃

Malignant Gastric Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID7216

Patients with high baseline plasma VEGF-A levels showed a trend toward improved overall survival (hazard ratio [HR], 0.72; 95% CI, 0.57 to 0.93) versus patients with low VEGF-A levels (HR, 1.01; 95% C… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC

civic

Bevacizumab + ErlotinibCombination

Malignant Ovarian Neoplasm

Predictive

Supports Resistance

submitted

EID7237

This phase II trial evaluated the efficacy of bevacizumab+erlotinib in 40 platinum-resistant ovarian cancer patients. No evidence was found associating VEGFR-1 expression and any clinical parameters.… (full text at CIViC)

PMID 21041183 · Chambers et al., 2010 · Open in CIViC

civic

VEGFA Overexpression of VEGF1212
Bevacizumab	GlioblastomaCURATED_BROADER	Predictive	B	Supports Resistance	4	submitted	EID9490 In a clinical study including 12 patients already treated with bevacizumab, high levels of plasma VEGF-121 decrease the OS and the PFS (p = 0.0246 and p = 0.0295) compared to low level of expression. PMID 29747600 · Martini et al., 2018 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	3	submitted	EID9297 Patients with high plasma VEGF121 levels treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.52; 95% CI, 0.33 to 0.81). The trend was not significant with patients wi… (full text at CIViC) PMID 23422754 · Miles et al., 2013 · Open in CIViC	civic

VEGFA Overexpression of VEGF1212

Bevacizumab

GlioblastomaCURATED_BROADER

Predictive

Supports Resistance

submitted

EID9490

In a clinical study including 12 patients already treated with bevacizumab, high levels of plasma VEGF-121 decrease the OS and the PFS (p = 0.0246 and p = 0.0295) compared to low level of expression.

PMID 29747600 · Martini et al., 2018 · Open in CIViC

civic

〃

HER2 Negative Breast CancerUNRESOLVED

Predictive

Supports Sensitivity Response

submitted

EID9297

Patients with high plasma VEGF121 levels treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.52; 95% CI, 0.33 to 0.81). The trend was not significant with patients wi… (full text at CIViC)

PMID 23422754 · Miles et al., 2013 · Open in CIViC

civic

VEGFA Overexpression of VEGF121 and VEGF1104
Bevacizumab	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID9300 Patients with high VEGF121and VEGF110 levels treated with bevacizumab compared to placebo show a trend toward improved PFS (HR 0.64, 95% CI, 0.47 to 0.88). The trend was not significant for patients w… (full text at CIViC) PMID 27817944 · Miles et al., 2017 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	3	submitted	EID9298 In a clinical trials of 774 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab compared to placebo showed a trend toward improved OS (HR 0.72; 95% CI, 0.57 to 0.93… (full text at CIViC) PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID9299 Patients with high VEGF121and VEGF110 levels treated with bevacizumab and chemotherapy compared to chemotherapy only show a trend toward improved PFS. However this trend is not significant (HR 0.64; 9… (full text at CIViC) PMID 23932548 · Cameron et al., 2013 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID9301 In a clinical trial of 161 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab plus trastuzumab plus docetaxel compared to trastuzumab plus docetaxel only show a tr… (full text at CIViC) PMID 23569311 · Gianni et al., 2013 · Open in CIViC	civic

VEGFA Overexpression of VEGF121 and VEGF1104

Bevacizumab

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9300

Patients with high VEGF121and VEGF110 levels treated with bevacizumab compared to placebo show a trend toward improved PFS (HR 0.64, 95% CI, 0.47 to 0.88). The trend was not significant for patients w… (full text at CIViC)

PMID 27817944 · Miles et al., 2017 · Open in CIViC

civic

〃

Malignant Gastric Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9298

In a clinical trials of 774 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab compared to placebo showed a trend toward improved OS (HR 0.72; 95% CI, 0.57 to 0.93… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC

civic

〃

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9299

Patients with high VEGF121and VEGF110 levels treated with bevacizumab and chemotherapy compared to chemotherapy only show a trend toward improved PFS. However this trend is not significant (HR 0.64; 9… (full text at CIViC)

PMID 23932548 · Cameron et al., 2013 · Open in CIViC

civic

〃

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9301

In a clinical trial of 161 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab plus trastuzumab plus docetaxel compared to trastuzumab plus docetaxel only show a tr… (full text at CIViC)

PMID 23569311 · Gianni et al., 2013 · Open in CIViC

civic

VEGFA overexpression of VEGF-Axxxa1
Bevacizumab	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID9290 In VEGF-Axxxa high cases, the median OS of patients treated with taxane only (cohort A) was 26 months while the median OS of patients treated with paclitaxel/bevacizumab (cohort B) was 41 months: beva… (full text at CIViC) PMID 24703319 · Pentheroudakis et al., 2014 · Open in CIViC	civic

VEGFA overexpression of VEGF-Axxxa1

Bevacizumab

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9290

In VEGF-Axxxa high cases, the median OS of patients treated with taxane only (cohort A) was 26 months while the median OS of patients treated with paclitaxel/bevacizumab (cohort B) was 41 months: beva… (full text at CIViC)

PMID 24703319 · Pentheroudakis et al., 2014 · Open in CIViC

civic

VEGFA VEGF165b Overexpression1
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Reduced Sensitivity	4	submitted	EID9289 Nude mice were injected with VEGF165b-transfected LS174t colon cancer cells or control LS174t cells and treated with bevacizumab. VEGF165b expressing tumors grew faster than those not expressing VEGF1… (full text at CIViC) PMID 18349829 · Varey et al., 2008 · Open in CIViC	civic

VEGFA VEGF165b Overexpression1

Bevacizumab

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Reduced Sensitivity

submitted

EID9289

Nude mice were injected with VEGF165b-transfected LS174t colon cancer cells or control LS174t cells and treated with bevacizumab. VEGF165b expressing tumors grew faster than those not expressing VEGF1… (full text at CIViC)

PMID 18349829 · Varey et al., 2008 · Open in CIViC

civic

Clinical evidence (16)

Alteration frequency by cohort (8)

Linked publications (1)